NDC 81565-202 Dexamethasone Sodium Phosphate

Dexamethasone Sodium Phosphate

NDC Product Code 81565-202

NDC CODE: 81565-202

Proprietary Name: Dexamethasone Sodium Phosphate What is the Proprietary Name?
The proprietary name also known as the trade name is the name of the product chosen by the medication labeler for marketing purposes.

Non-Proprietary Name: Dexamethasone Sodium Phosphate What is the Non-Proprietary Name?
The non-proprietary name is sometimes called the generic name. The generic name usually includes the active ingredient(s) of the product.

Drug Use Information

Drug Use Information
The drug use information is a summary and does NOT have all possible information about this product. This information does not assure that this product is safe, effective, or appropriate. This information is not individual medical advice and does not substitute for the advice of a health care professional. Always ask a health care professional for complete information about this product and your specific health needs.

  • Dexamethasone is used to treat conditions such as arthritis, blood/hormone disorders, allergic reactions, skin diseases, eye problems, breathing problems, bowel disorders, cancer, and immune system disorders. It is also used as a test for an adrenal gland disorder (Cushing's syndrome). Dexamethasone belongs to a class of drugs known as corticosteroids. It decreases your immune system's response to various diseases to reduce symptoms such as swelling and allergic-type reactions. This injectable form of dexamethasone is used when a similar drug cannot be taken by mouth or when a very fast response is needed, especially in patients with severe medical conditions. Talk to your doctor about the risks and benefits of dexamethasone, especially if it is to be injected near your spine (epidural). Rare but serious side effects may occur with epidural use.

NDC Code Structure

  • 81565 - Phlow Corporation

NDC 81565-202-02

Package Description: 25 VIAL in 1 TRAY > 1 mL in 1 VIAL (81565-202-01)

NDC Product Information

Dexamethasone Sodium Phosphate with NDC 81565-202 is a a human prescription drug product labeled by Phlow Corporation. The generic name of Dexamethasone Sodium Phosphate is dexamethasone sodium phosphate. The product's dosage form is injection, solution and is administered via intramuscular; intravenous form. The RxNorm Crosswalk for this NDC code indicates a single RxCUI concept is associated to this product: 1812194.

Dosage Form: Injection, Solution - A liquid preparation containing one or more drug substances dissolved in a suitable solvent or mixture of mutually miscible solvents that is suitable for injection.

Product Type: Human Prescription Drug What kind of product is this?
Indicates the type of product, such as Human Prescription Drug or Human Over the Counter Drug. This data element matches the “Document Type” field of the Structured Product Listing.

Dexamethasone Sodium Phosphate Active Ingredient(s)

What is the Active Ingredient(s) List?
This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted.

Inactive Ingredient(s)

About the Inactive Ingredient(s)
The inactive ingredients are all the component of a medicinal product OTHER than the active ingredient(s). The acronym "UNII" stands for “Unique Ingredient Identifier” and is used to identify each inactive ingredient present in a product.

  • WATER (UNII: 059QF0KO0R)

Administration Route(s)

What are the Administration Route(s)?
The translation of the route code submitted by the firm, indicating route of administration.

  • Intramuscular - Administration within a muscle.
  • Intravenous - Administration within or into a vein or veins.

Pharmacological Class(es)

What is a Pharmacological Class?
These are the reported pharmacological class categories corresponding to the SubstanceNames listed above.

  • Corticosteroid - [EPC] (Established Pharmacologic Class)
  • Corticosteroid Hormone Receptor Agonists - [MoA] (Mechanism of Action)

Product Labeler Information

What is the Labeler Name?
Name of Company corresponding to the labeler code segment of the Product NDC.

Labeler Name: Phlow Corporation
Labeler Code: 81565
FDA Application Number: ANDA084916 What is the FDA Application Number?
This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. “part 341”). For unapproved drugs, this field will be null.

Marketing Category: ANDA - A product marketed under an approved Abbreviated New Drug Application. What is the Marketing Category?
Product types are broken down into several potential Marketing Categories, such as NDA/ANDA/BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.

Start Marketing Date: 12-15-2021 What is the Start Marketing Date?
This is the date that the labeler indicates was the start of its marketing of the drug product.

Listing Expiration Date: 12-31-2022 What is the Listing Expiration Date?
This is the date when the listing record will expire if not updated or certified by the product labeler.

Exclude Flag: N - NO What is the NDC Exclude Flag?
This field indicates whether the product has been removed/excluded from the NDC Directory for failure to respond to FDA"s requests for correction to deficient or non-compliant submissions ("Y"), or because the listing certification is expired ("E"), or because the listing data was inactivated by FDA ("I"). Values = "Y", "N", "E", or "I".

* Please review the disclaimer below.

Dexamethasone Sodium Phosphate Product Labeling Information

The product labeling information includes all published material associated to a drug. Product labeling documents include information like generic names, active ingredients, ingredient strength dosage, routes of administration, appearance, usage, warnings, inactive ingredients, etc.

Product Labeling Index


Rx only

Mfd for: Richmond, VA 23219www.Phlow-USA.comMfd by:Fresenius KabiLake Zurich, IL 60047451723November 2021


Dexamethasone sodium phosphate is a water-soluble inorganic ester of dexamethasone.  It occurs as a white or slightly yellow crystalline powder, is odorless or has a slight odor of alcohol, is exceedingly hygroscopic and is freely soluble in water.  Dexamethasone sodium phosphate is an adrenocortical steroid anti-inflammatory drug.  Chemically, dexamethasone sodium phosphate is 9-Fluoro-11ß,17,21-trihydroxy-16α-methylpregna-1, 4-diene-3,20-dione 21-(dihydrogen phosphate) disodium salt and has the following structural formula:  Dexamethasone Sodium Phosphate Injection, USP is a sterile solution of dexamethasone sodium phosphate in water for injection for intravenous (IV), intramuscular (IM), intra-articular, soft-tissue or intralesional use.  Each mL contains dexamethasone sodium phosphate equivalent to dexamethasone phosphate 4 mg or dexamethasone 3.33 mg; benzyl alcohol 10 mg added as preservative; sodium citrate dihydrate 11 mg; sodium sulfite 1 mg as an antioxidant; Water for Injection q.s.  Citric acid and/or sodium hydroxide may have been added for pH adjustment (7.0 to 8.5).  Air in the container is displaced by nitrogen.

Clinical Pharmacology:

Dexamethasone sodium phosphate has a rapid onset but short duration of action when compared with less soluble preparations.  Because of this, it is suitable for the treatment of acute disorders responsive to adrenocortical steroid therapy.  Naturally occurring glucocorticoids (hydrocortisone and cortisone), which also have salt-retaining properties, are used as replacement therapy in adrenocortical deficiency states.  Their synthetic analogs, including dexamethasone, are primarily used for their potent anti-inflammatory effects in disorders of many organ systems.  Glucocorticoids cause profound and varied metabolic effects.  In addition, they modify the body’s immune responses to diverse stimuli.  At equipotent anti-inflammatory doses, dexamethasone almost completely lacks the sodium-retaining property of hydrocortisone and closely related derivatives of hydrocortisone.

Indications And Usage:

Intravenous or Intramuscular InjectionWhen oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, those products labeled for intravenous or intramuscular use are indicated as follows:• Endocrine Disorders     Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance)     Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used)     Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful     Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected     Congenital adrenal hyperplasia     Nonsuppurative thyroiditis     Hypercalcemia associated with cancer• Rheumatic Disorders     As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in:     Post-traumatic osteoarthritis     Synovitis of osteoarthritis     Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy)     Acute and subacute bursitis      Epicondylitis     Acute nonspecific tenosynovitis     Acute gouty arthritis     Psoriatic arthritis     Ankylosing spondylitis• Collagen Diseases     During an exacerbation or as maintenance therapy in selected cases of:     Systemic lupus erythematosus     Acute rheumatic carditis• Dermatologic Diseases     Pemphigus     Severe erythema multiforme (Stevens-Johnson syndrome)     Exfoliative dermatitis     Bullous dermatitis herpetiformis     Severe seborrheic dermatitis     Severe psoriasis     Mycosis fungoides• Allergic States     Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in:     Bronchial asthma     Contact dermatitis     Atopic dermatitis     Serum sickness     Seasonal or perennial allergic rhinitis     Drug hypersensitivity reactions     Urticarial transfusion reactions     Acute noninfectious laryngeal edema (epinephrine is the drug of first choice)• Ophthalmic Diseases     Severe acute and chronic allergic and inflammatory processes involving the eye, such as:     Herpes zoster ophthalmicus     Iritis, iridocyclitis     Chorioretinitis     Diffuse posterior uveitis and choroiditis     Optic neuritis     Sympathetic ophthalmia     Anterior segment inflammation     Allergic conjunctivitis     Keratitis     Allergic corneal marginal ulcers• Gastrointestinal Diseases     To tide the patient over a critical period of the disease in:     Ulcerative colitis (Systemic therapy)     Regional enteritis (Systemic therapy)• Respiratory Diseases     Symptomatic sarcoidosis     Berylliosis     Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy     Loeffler’s syndrome not manageable by other means     Aspiration pneumonitis• Hematologic Disorders     Acquired (autoimmune) hemolytic anemia      Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated)     Secondary thrombocytopenia in adults     Erythroblastopenia (RBC anemia)     Congenital (erythroid) hypoplastic anemia• Neoplastic Diseases     For palliative management of:     Leukemias and lymphomas in adults     Acute leukemia of childhood• Edematous States     To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type, or that due to lupus erythematosus• Miscellaneous     Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy     Trichinosis with neurologic or myocardial involvement• Diagnostic testing of adrenocortical hyperfunction• Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury.     Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy.

By Intra-Articular Or Soft Tissue Injection

As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in:     Synovitis of osteoarthritis     Rheumatoid arthritis     Acute and subacute bursitis     Acute gouty arthritis     Epicondylitis     Acute nonspecific tenosynovitis     Post-traumatic osteoarthritis

By Intralesional Injection

Keloids     Localized hypertrophic, infiltrated, inflammatory lesions of: lichen planus, psoriatic plaques, granuloma annulare and lichen simplex chronicus (neurodermatitis)     Discoid lupus erythematosus     Necrobiosis lipoidica diabeticorum     Alopecia areata     May also be useful in cystic tumors of an aponeurosis or tendon (ganglia)


Systemic fungal infections (see WARNINGS regarding amphotericin B).  Hypersensitivity to any component of this product, including sulfites (see WARNINGS).


Because rare instances of anaphylactoid reactions have occurred in patients receiving parenteral corticosteroid therapy, appropriate precautionary measures should be taken prior to administration, especially when the patient has a history of allergy to any drug.  Anaphylactoid and hypersensitivity reactions have been reported for dexamethasone sodium phosphate (see ADVERSE REACTIONS).Dexamethasone sodium phosphate injection contains sodium bisulfite, a sulfite that may cause allergic-type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people.  The overall prevalence of sulfite sensitivity in the general population is unknown and probably low.  Sulfite sensitivity is seen more frequently in asthmatic than in non-asthmatic people.Corticosteroids may exacerbate systemic fungal infections and therefore, should not be used in the presence of such infections unless they are needed to control drug reactions due to amphotericin B.   Moreover, there have been cases reported in which concomitant use of amphotericin B and hydrocortisone was followed by cardiac enlargement and congestive failure.In patients on corticosteroid therapy subjected to any unusual stress, increased dosage of rapidly acting corticosteroids before, during, and after the stressful situation is indicated.Drug-induced secondary adrenocortical insufficiency may result from too rapid withdrawal of corticosteroids and may be minimized by gradual reduction of dosage.  This type of relative insufficiency may persist for months after discontinuation of therapy; therefore, in any situation of stress occurring during that period, hormone therapy should be reinstituted.  If the patient is receiving steroids already, dosage may have to be increased.  Since mineralocorticoid secretion may be impaired, salt and/or a mineralocorticoid should be administered concurrently.Corticosteroids may mask some signs of infection, and new infections may appear during their use.  There may be decreased resistance and inability to localize infection when corticosteroids are used.  Moreover, corticosteroids may affect the nitroblue-tetrazolium test for bacterial infection and produce false negative results.In cerebral malaria, a double-blind trial has shown that the use of corticosteroids is associated with prolongation of coma and a higher incidence of pneumonia and gastrointestinal bleeding.Corticosteroids may activate latent amebiasis.  Therefore, it is recommended that latent or active amebiasis be ruled out before initiating corticosteroid therapy in any patient who has spent time in the tropics or any patient with unexplained diarrhea.Prolonged use of corticosteroids may produce posterior subcapsular cataracts, glaucoma with possible damage to the optic nerves, and may enhance the establishment of secondary ocular infections due to fungi or viruses.Average and large doses of cortisone or hydrocortisone can cause elevation of blood pressure, salt and water retention, and increased excretion of potassium.  These effects are less likely to occur with the synthetic derivatives except when used in large doses.  Dietary salt restriction and potassium supplementation may be necessary.  All corticosteroids increase calcium excretion.Administration of live virus vaccines, including smallpox, is contraindicated in individuals receiving immunosuppressive doses of corticosteroids.  If inactivated viral or bacterial vaccines are administered to individuals receiving immunosuppressive doses of corticosteroids, the expected serum antibody response may not be obtained.  However, immunization procedures may be undertaken in patients who are receiving corticosteroids as replacement therapy, e.g., for Addison’s disease.Persons who are on drugs which suppress the immune system are more susceptible to infections than healthy individuals.  Chickenpox and measles, for example, can have a more serious or even fatal course in non-immune children or adults on corticosteroids.  In such children or adults who have not had these diseases, particular care should be taken to avoid exposure.  How the dose, route and duration of corticosteroid administration affects the risk of developing a disseminated infection is not known.  The contribution of the underlying disease and/or prior corticosteroid treatment to the risk is also not known.  If exposed to chickenpox, prophylaxis with varicella zoster immune globulin (VZIG) may be indicated.  If exposed to measles, prophylaxis with pooled intramuscular immunoglobulin (IG) may be indicated.  (See the respective package inserts for complete VZIG and IG prescribing information).  If chickenpox develops, treatment with antiviral agents may be considered.The use of dexamethasone sodium phosphate in active tuberculosis should be restricted to those cases of fulminating or disseminated tuberculosis in which the corticosteroid is used for the management of the disease in conjunction with an appropriate antituberculous regimen.If corticosteroids are indicated in patients with latent tuberculosis or tuberculin reactivity, close observation is necessary as reactivation of the disease may occur.  During prolonged corticosteroid therapy, these patients should receive chemoprophylaxis.Literature reports suggest an apparent association between use of corticosteroids and left ventricular free wall rupture after a recent myocardial infarction; therefore, therapy with corticosteroids should be used with great caution in these patients.

Serious Neurologic Adverse Reactions With Epidural Administration

Serious neurologic events, some resulting in death, have been reported with epidural injection of corticosteroids.  Specific events reported include, but are not limited to, spinal cord infarction, paraplegia, quadriplegia, cortical blindness, and stroke.  These serious neurologic events have been reported with and without use of fluoroscopy.  The safety and effectiveness of epidural administration of corticosteroids has not been established, and corticosteroids are not approved for this use.


Teratogenic Effects: Pregnancy Category C–Since adequate human reproduction studies have not been done with corticosteroids, use of these drugs in pregnancy or in women of childbearing potential requires that the anticipated benefits be weighed against the possible hazards to the mother and embryo or fetus.  Infants born of mothers who have received substantial doses of corticosteroids during pregnancy should be carefully observed for signs of hypoadrenalism.Corticosteroids appear in breast milk and could suppress growth, interfere with endogenous corticosteroid production, or cause other unwanted effects.  Mothers taking pharmacologic doses of corticosteroids should be advised not to nurse.


This product, like many other steroid formulations, is sensitive to heat.  Therefore, it should not be autoclaved when it is desirable to sterilize the exterior of the vial.Following prolonged therapy, withdrawal of corticosteroids may result in symptoms of the corticosteroid withdrawal syndrome including fever, myalgia, arthralgia, and malaise.  This may occur in patients even without evidence of adrenal insufficiency.There is an enhanced effect of corticosteroids in patients with hypothyroidism and in those with cirrhosis.Corticosteroids should be used cautiously in patients with ocular herpes simplex for fear of corneal perforation.The lowest possible dose of corticosteroid should be used to control the condition under treatment, and when reduction in dosage is possible, the reduction must be gradual.Psychic derangements may appear when corticosteroids are used, ranging from euphoria, insomnia, mood swings, personality changes, and severe depression to frank psychotic manifestations.  Also, existing emotional instability or psychotic tendencies may be aggravated by corticosteroids.Aspirin should be used cautiously in conjunction with corticosteroids in hypoprothrombinemia.Steroids should be used with caution in nonspecific ulcerative colitis, if there is a probability of impending perforation, abscess, or other pyogenic infection, also in diverticulitis, fresh intestinal anastomoses, active or latent peptic ulcer, renal insufficiency, hypertension, osteoporosis, and myasthenia gravis.  Signs of peritoneal irritation following gastrointestinal perforation in patients receiving large doses of corticosteroids may be minimal or absent.  Fat embolism has been reported as a possible complication of hypercortisonism.When large doses are given, some authorities advise that antacids be administered between meals to help to prevent peptic ulcer.Growth and development of infants and children on prolonged corticosteroid therapy should be carefully followed.Steroids may increase or decrease motility and number of spermatozoa in some patients.Phenytoin, phenobarbital, ephedrine, and rifampin may enhance the metabolic clearance of corticosteroids resulting in decreased blood levels and lessened physiologic activity, thus requiring adjustment in corticosteroid dosage.  These interactions may interfere with dexamethasone suppression tests which should be interpreted with caution during administration of these drugs.False negative results in the dexamethasone suppression test (DST) in patients being treated with indomethacin have been reported.  Thus, results of the DST should be interpreted with caution in these patients.The prothrombin time should be checked frequently in patients who are receiving corticosteroids and coumarin anticoagulants at the same time because of reports that corticosteroids have altered the response to these anticoagulants.  Studies have shown that the usual effect produced by adding corticosteroids is inhibition of response to coumarins, although there have been some conflicting reports of potentiation not substantiated by studies.When corticosteroids are administered concomitantly with potassium-depleting diuretics, patients should be observed closely for development of hypokalemia.Intra-articular injection of a corticosteroid may produce systemic as well as local effects.Appropriate examination of any joint fluid present is necessary to exclude a septic process.A marked increase in pain accompanied by local swelling, further restriction of joint motion, fever, and malaise is suggestive of septic arthritis.  If this complication occurs and the diagnosis of sepsis is confirmed, appropriate antimicrobial therapy should be instituted.Injection of a steroid into an infected site is to be avoided.Corticosteroids should not be injected into unstable joints.Patients should be impressed strongly with the importance of not overusing joints in which symptomatic benefit has been obtained as long as the inflammatory process remains active.Frequent intra-articular injection may result in damage to joint tissues.  The slower rate of absorption by intramuscular administration should be recognized.

Information For Patients

Persons who are on immunosuppressant doses of corticosteroids should be warned to avoid exposure to chickenpox or measles.  Patients should also be advised that if they are exposed, medical advice should be sought without delay.

Adverse Reactions:

Fluid and electrolyte disturbances:     Sodium retention     Fluid retention     Congestive heart failure in susceptible patients     Potassium loss     Hypokalemic alkalosis     HypertensionMusculoskeletal:     Muscle weakness     Steroid myopathy     Loss of muscle mass     Osteoporosis     Pathologic fracture of long bones     Vertebral compression fractures     Aseptic necrosis of femoral and humeral heads     Tendon ruptureGastrointestinal:     Peptic ulcer with possible subsequent perforation and hemorrhage     Perforation of the small and large bowel, particularly in patients with inflammatory bowel disease     Pancreatitis     Abdominal distention     Ulcerative esophagitisDermatologic:     Impaired wound healing     Thin fragile skin     Petechiae and ecchymoses     Erythema     Increased sweating     May suppress reactions to skin tests     Burning or tingling, especially in the perineal area (after IV injection)     Other cutaneous reactions, such as allergic dermatitis, urticaria, angioneurotic edemaNeurologic:     Convulsions     Increased intracranial pressure with papilledema (pseudotumor cerebri) usually after treatment     Vertigo     Headache     Psychic disturbancesEndocrine:     Menstrual irregularities     Development of cushingoid state     Suppression of growth in children     Secondary adrenocortical and pituitary unresponsiveness, particularly in times of stress, as in trauma, surgery, or illness     Decreased carbohydrate tolerance     Manifestations of latent diabetes mellitus     Increased requirements for insulin or oral hypoglycemic agents in diabetics     HirsutismOphthalmic:     Posterior subcapsular cataracts     Increased intraocular pressure     Glaucoma     ExophthalmosMetabolic:     Negative nitrogen balance due to protein catabolismCardiovascular:     Myocardial rupture following recent myocardial infarction (see WARNINGS)Other:     Anaphylactoid or hypersensitivity reactions     Thromboembolism     Weight gain     Increased appetite     Nausea     Malaise     Hiccups     The following additional adverse reactions are related to parenteral corticosteroid therapy:     Rare instances of blindness associated with intralesional therapy around the face and head     Hyperpigmentation or hypopigmentation     Subcutaneous and cutaneous atrophy     Sterile abscess     Post-injection flare (following intra-articular use)     Charcot-like arthropathyTo report SUSPECTED ADVERSE REACTIONS, contact Fresenius Kabi USA, LLC at 1-800-551-7176 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.


Reports of acute toxicity and/or death following overdosage of glucocorticoids are rare.  In the event of overdosage, no specific antidote is available; treatment is supportive and symptomatic.The oral LD50 of dexamethasone in female mice was 6.5 g/kg.  The intravenous LD50 of dexamethasone sodium phosphate in female mice was 794 mg/kg.

Dosage And Administration:

Dexamethasone sodium phosphate injection, 4 mg per mL– For intravenous, intramuscular, intra-articular, intralesional, and soft tissue injection.Dexamethasone sodium phosphate injection can be given directly from the vial, or it can be added to Sodium Chloride Injection or Dextrose Injection and administered by intravenous drip.Solutions used for intravenous administration or further dilution of this product should be preservative free when used in the neonate, especially the premature infant.When it is mixed with an infusion solution, sterile precautions should be observed.  Since infusion solutions generally do not contain preservatives, mixtures should be used within 24 hours.DOSAGE REQUIREMENTS ARE VARIABLE AND MUST BE INDIVIDUALIZED ON THE BASIS OF THE DISEASE AND THE RESPONSE OF THE PATIENT.

Intravenous And Intramuscular Injection:

The initial dosage of dexamethasone sodium phosphate injection varies from 0.5 to 9 mg a day depending on the disease being treated.  In less severe diseases doses lower than 0.5 mg may suffice, while in severe diseases doses higher than 9 mg may be required.The initial dosage should be maintained or adjusted until the patient’s response is satisfactory.  If a satisfactory clinical response does not occur after a reasonable period of time, discontinue dexamethasone sodium phosphate injection and transfer the patient to other therapy.After a favorable initial response, the proper maintenance dosage should be determined by decreasing the initial dosage in small amounts to the lowest dosage that maintains an adequate clinical response.Patients should be observed closely for signs that might require dosage adjustment, including changes in clinical status resulting from remissions or exacerbations of the disease, individual drug responsiveness, and the effect of stress (e.g., surgery, infection, trauma).  During stress it may be necessary to increase dosage temporarily.If the drug is to be stopped after more than a few days of treatment, it usually should be withdrawn gradually.When the intravenous route of administration is used, dosage usually should be the same as the oral dosage.  In certain overwhelming, acute, life-threatening situations, however, administration in dosages exceeding the usual dosages may be justified and may be in multiples of the oral dosages.  The slower rate of absorption by intramuscular administration should be recognized.


There is a tendency in current medical practice to use high (pharmacologic) doses of corticosteroids for the treatment of unresponsive shock.  The following dosages of dexamethasone sodium phosphate injection have been suggested by various authors: Author DosageCavanagh13 mg/kg of body weight per 24 hours by constant intravenous infusion after an initial intravenous injection of 20 mgDietzman22 to 6 mg/kg of body weight as a single intravenous injectionFrank340 mg initially followed by repeatintravenous injection every 4 to 6 hours while shock persistsOaks440 mg initially followed by repeatintravenous injection every 2 to 6 hours while shock persistsSchumer51 mg/kg of body weight as a single intravenous injectionAdministration of high dose corticosteroid therapy should be continued only until the patient’s condition has stabilized and usually not longer than 48 to 72 hours.Although adverse reactions associated with high dose, short term corticosteroid therapy are uncommon, peptic ulceration may occur.

Cerebral Edema

Dexamethasone sodium phosphate injection is generally administered initially in a dosage of 10 mg intravenously followed by four mg every six hours intramuscularly until the symptoms of cerebral edema subside.  Response is usually noted within 12 to 24 hours and dosage may be reduced after two to four days and gradually discontinued over a period of five to seven days.  For palliative management of patients with recurrent or inoperable brain tumors, maintenance therapy with two mg two or three times a day may be effective.

Acute Allergic Disorders

In acute, self-limited allergic disorders or acute exacerbations of chronic allergic disorders, the following dosage schedule combining parenteral and oral therapy is suggested:Dexamethasone sodium phosphate injection, 4 mg per mL: first day, 1 or 2 mL (4 or 8 mg), intramuscularly.Dexamethasone tablets, 0.75 mg: second and third days, 4 tablets in two divided doses each day; fourth day, 2 tablets in two divided doses; fifth and sixth days, 1 tablet each day; seventh day, no treatment; eighth day, follow-up visit.This schedule is designed to ensure adequate therapy during acute episodes, while minimizing the risk of overdosage in chronic cases.

Intra-Articular, Intralesional And Soft Tissue Injection

Intra-articular, intralesional, and soft tissue injections are generally employed when the affected joints or areas are limited to one or two sites.  Dosage and frequency of injection varies depending on the condition and the site of injection.  The usual dose is from 0.2 to 6 mg.  The frequency usually ranges from once every three to five days to once every two to three weeks.  Frequent intra-articular injection may result in damage to joint tissues.Some of the usual single doses are:  Site of Injection  Amount of DexamethasonePhosphate (mg)Large Joints(e.g., Knee) 2 to 4 Small Joints(e.g., Interphalangeal,Temporomandibular) 0.8 to 1 Bursae 2 to 3 Tendon Sheaths 0.4 to 1 Soft Tissue Infiltration 2 to 6 Ganglia 1 to 2 Dexamethasone sodium phosphate injection is particularly recommended for use in conjunction with one of the less soluble, longer-acting steroids for intra-articular and soft tissue injection.Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever the solution and container permit.

How Supplied:

Product CodeUnit of SalePC16501
NDC 81565-202-021 mL fill, in a 2 mL flip-top vial, packaged in 25.
StrengthEachDexamethasone Sodium Phosphate Injection, USP (equivalent to 4 mg per mL dexamethasone phosphate)
NDC 81565-202-011 mL fill, in a 2 mL flip-top vial.
STORE AT:  20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature].  Protect from freezing.  Sensitive to heat.  Do not autoclave.   Protect from light. Store container in carton until contents have been used.   Do not use if precipitate is present.


  • Cavanagh, D.; Singh, K.B.: Endotoxin shock in pregnancy and abortion, in: “Corticosteroids in the Treatment of Shock”, Schumer, W.; Nyhus, L.M., Editors, Urbana, University of Illinois Press, 1970, pp. 86-96.Dietzman, R.H.; Ersek, R.A.; Bloch, J.M.; Lillehei, R.C.: High-output, low-resistance gram-negative septic shock in man, Angiology 20: 691-700, Dec. 1969.Frank, E.: Clinical observations in shock and management (In: Shields, T.F., ed.: Symposium on current concepts and management of shock), J. Maine Med. Ass. 59: 195-200, Oct. 1968.Oaks, W. W.; Cohen, H.E.: Endotoxin shock in the geriatric patient, Geriat. 22: 120-130, Mar. 1967.Schumer, W.; Nyhus, L.M.: Corticosteroid effect on biochemical parameters of human oligemic shock, Arch. Surg. 100: 405-408, Apr. 1970.

* Please review the disclaimer below.